Shares of Moderna MRNA have staged a remarkable comeback this year as investors increasingly warm to the possibility that the company can rebuild its business beyond COVID-19 vaccines. After becoming one of the biggest pandemic winners, Moderna struggled with sharply lower COVID-19 vaccine demand, declining revenues and mounting losses, sending its stock tumbling from its pandemic-era highs.
Read on zacks.com